Pacira BioSciences Grants Inducement Awards to 14 Employees
Pacira BioSciences announced the granting of inducement awards on February 3, 2026 to 14 new employees under Pacira's Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors without stockholder approval. Four employees received stock options to purchase an aggregate of 58,000 shares of Pacira common stock and 14 employees received restricted stock units for an aggregate of 41,300 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient's first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $21.02 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on February 1, 2027. Vesting of the equity awards is subject to the employee's continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.
Trade with 70% Backtested Accuracy
Analyst Views on PCRX
About PCRX
About the author

- Shareholder Voting Appeal: Pacira BioSciences urges shareholders to support its three board nominees at the upcoming 2026 Annual Meeting, emphasizing the company's leadership in non-opioid pain therapies and aiming to protect shareholder investments through stable leadership and strategic execution.
- Strong Financial Performance: In 2025, Pacira achieved total revenues of $726.4 million, with GAAP net income of $7 million and non-GAAP net income reaching $122.3 million, demonstrating a more than 31% increase in stock price following the implementation of its 5x30 strategy, indicating a robust recovery in market momentum.
- Expanded Treatment Coverage: In 2025, Pacira's products treated over 2.5 million patients, progressing towards its goal of helping 3 million patients annually by 2030, with EXPAREL achieving a year-over-year growth rate of 6.2%, showcasing the company's sustained growth potential in the non-opioid pain management market.
- Strengthened Intellectual Property Strategy: Pacira reached a favorable settlement with Fresenius Kabi regarding EXPAREL, ensuring exclusivity until 2030, which enhances the company's competitive position in the market, while expanding its patent portfolio to prevent future competition and secure long-term shareholder value creation.
- New Company Listing: Conexeu Sciences Inc. debuted on Nasdaq on May 21, 2026, with over 25.2 million shares issued, as CEO emphasized their CXU™ platform's goal to rebuild biological structures, potentially attracting significant investor interest in regenerative medicine.
- Significant Revenue Growth: Pacira BioSciences achieved total revenue of $726.4 million in 2025, with gross margins at a historic high of 79.4%, reflecting strong demand for its non-opioid pain therapies, which may lead to increased capital inflows into related companies.
- Bioprinting Infrastructure: Stratasys reported $237.8 million in cash and equivalents with no debt in Q1 2026, and its TrueDent® resins received CE marking, enhancing its penetration in the European market and strengthening the bioprinting industry's infrastructure.
- Wound Care Innovation: Smith & Nephew launched ALLEVYN COMPLETE CARE Foam Dressing in the U.S. in March 2026, targeting chronic wound management with robust scientific backing, addressing the growing global demand for wound care and further expanding the regenerative medicine market.
- New Listing: Conexeu Sciences Inc. debuted on Nasdaq on May 21, 2026, with 25,269,996 shares issued, as CEO emphasized the CXU™ platform's goal to rebuild biological architecture, targeting over 100,000 women annually for breast reconstruction.
- Revenue Growth: Pacira BioSciences achieved total revenue of $726.4 million in 2025 with a GAAP gross margin of 79.4%, reflecting strong market demand for non-opioid pain therapies, which is driving capital back into early-stage regenerative medicine companies.
- Bioprinting Infrastructure: Stratasys reported $237.8 million in cash and short-term deposits with no debt in Q1 2026, and its TrueDent® resins received CE marking, marking a significant advancement in its bioprinting technology in the European market.
- Wound Care Innovation: Smith & Nephew launched the ALLEVYN COMPLETE CARE Foam Dressing in the U.S. on March 10, 2026, addressing the global demand for advanced wound care products, further propelling the commercialization of regenerative medicine.
- Board Election Call: Shareholders of Pacira BioSciences are urged to support the election of Christopher Dennis and Oliver Benton Curtis III, backed by DOMA Perpetual Capital Management, to bring fresh perspectives and rigorous questioning to the board, despite management's criticisms of their credibility.
- Independence and Qualifications: Dennis and Curtis emphasize that they conducted independent due diligence before agreeing to run, discovering that the company possesses real assets and a commendable non-opioid pain mission, yet the current governance structure has failed to deliver the returns shareholders deserve.
- Growth Potential Questioned: The candidates challenge management's narrative of a 5% topline growth success story, suggesting that with a federal reimbursement catalyst now active and commercial coverage expanded to 110 million lives, shareholders should consider whether this growth represents merely the early ceiling of the existing strategy.
- Shareholder Rights Focus: DOMA Perpetual owns approximately 7.5% of Pacira's common stock, indicating a strong interest in the company's governance and strategic direction, aiming to drive higher shareholder value.
- Persistent Underperformance: Since Frank Lee became CEO, Pacira's total shareholder return has plummeted by 46% over the past decade and 64% over the last five years, indicating a failure in management to enhance company value and protect shareholder interests.
- Mismanagement of Patent Risks: Pacira faces significant risks in its EXPAREL patent litigation, with management failing to establish effective contingency plans, which could lead to the loss of its core asset and exacerbate financial losses for shareholders.
- Unclear Strategic Direction: DOMA criticizes Pacira's 5x30 plan as illogical and ineffective in addressing potential legal risks, suggesting that management's goal-setting does not create predictable value for shareholders and may lead to wasted resources.
- Controversial Executive Compensation: Despite the company's poor performance, Frank Lee received $28 million in compensation over the past two years, raising concerns among shareholders about management prioritizing personal financial gain over the long-term development of the company.
- Shareholder Voting Appeal: DOMA Perpetual Capital Management, owning approximately 7.5% of Pacira BioSciences, urges shareholders to support its three nominees via the WHITE proxy card to drive meaningful change in the board, thereby enhancing governance and shareholder value.
- Performance Scrutiny: While Pacira's stock has risen over 30% since January 2025, the board's letter fails to benchmark the company against pharmaceutical peers, prompting shareholders to focus on the overall performance over the past three and five years to assess the effectiveness of its strategy.
- Revenue Growth Analysis: In Q1 2026, Pacira reported a 5% year-over-year revenue growth, achieved under the full effect of the NOPAIN Act, leading shareholders to question whether this growth reflects the success claimed by management or merely the early ceiling of the existing strategy.
- Commitment to Board Review: If elected, the nominees pledge to conduct a comprehensive independent review of strategic alternatives, including standalone plans, sales, or mergers, ensuring the board makes informed decisions based on real data.








